Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.
about
Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertensionDeterminants of patient adherence: a review of systematic reviews.Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy.Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utilityAntihypertensive drug treatment changes in the general population: the CoLaus studyEffect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records.Role of olmesartan in combination therapy in blood pressure control and vascular function.Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.Adverse effect profile of trichlormethiazide: a retrospective observational study.Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice.Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study.Antihypertensive drug class and adherence: an electronic monitoring studyMulticenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life--a prospective study.Barriers to cardiovascular risk prevention and management in Germany--an analysis of the EURIKA study.A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study.Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUEHypertension and aging.Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination in the treatment of hypertension.Renin-angiotensin system blocking drugs.The cost-effectiveness of irbesartan for hypertension.Interventions to Improve Medication Adherence in Hypertensive Patients: Systematic Review and Meta-analysisBlood pressure outcomes of medication adherence interventions: systematic review and meta-analysis.Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry.Primary non-adherence in Portugal: findings and implications.Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care.Prevalence and control of high blood pressure in primary care: results from the German Metabolic and Cardiovascular Risk Study (GEMCAS).
P2860
Q26824261-ED45DB69-1D26-4FA5-B728-528962390A5DQ30541800-E918EBE3-6254-4C02-8F5A-5263A8247F09Q33536143-2486A23D-B3DC-4E46-8310-CDF94D969C9BQ33571219-425ED3FA-43F5-49E1-9F1B-EAF57F6FB268Q33614990-2AD3870F-FD68-4CF6-B55D-12A64DD4448DQ33659515-3AFD5604-882F-46C1-884F-E5D32E739C98Q34139061-04885906-FFD8-43F8-B3EE-CDBE3C407A03Q34312115-E5F88636-4B59-45B7-9FDD-FEFF15AE3581Q34629402-BCE88A16-962F-4EFE-A702-EDAD143C0213Q34764232-96C8AC4D-3143-4317-9FED-AFFF3ADAC2A2Q35658906-676F6799-A1D5-4532-A8B5-EEE4DE71190FQ35661858-EE86DC34-2C0A-4F00-84B8-A234ABE89F71Q35878432-CF752E99-2787-408D-8C6F-5C72CE7BB0B1Q35905575-49599485-4D52-4E1F-9393-05047B48A1E3Q36045983-615026FC-333E-493C-B9F9-371FF7EDF093Q36510353-9D54E314-D6B3-44E5-9AE9-CA7F64C05E41Q36623143-EC84CA4C-24A0-49EC-96A2-1E3C833E79E2Q37671457-D121A6BD-40E9-47CE-9000-6B6678C47B10Q38050865-2078E1A8-BAAC-4EDE-8F8A-A0845C35A519Q38137851-E9057A05-8881-4F06-8876-35696F5D90FCQ38363840-F0C4826A-F1C0-4486-959B-5025954A06AFQ38631156-2EBB0F6A-1D65-4DA6-A236-CCB24E6ECFE5Q38770708-31A98DD9-2D32-4253-9EB6-B147BED59A07Q40804716-C9442F76-9723-43E0-9193-9A8A994A1C5CQ41127005-09C1F888-DBEB-4915-B9D2-D59A7516A673Q42867397-E6D6D998-1897-45ED-973A-0DF3744D8316Q43992225-35298C60-63A2-43E8-82BD-D54DDE67ADFA
P2860
Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Blood pressure reduction, pers ...... sive drug treatment--a review.
@en
Blood pressure reduction, pers ...... sive drug treatment--a review.
@nl
type
label
Blood pressure reduction, pers ...... sive drug treatment--a review.
@en
Blood pressure reduction, pers ...... sive drug treatment--a review.
@nl
prefLabel
Blood pressure reduction, pers ...... sive drug treatment--a review.
@en
Blood pressure reduction, pers ...... sive drug treatment--a review.
@nl
P2860
P356
P1476
Blood pressure reduction, pers ...... nsive drug treatment--a review
@en
P2093
Joerg Hasford
P2860
P2888
P356
10.1186/1475-2840-8-18
P407
P5008
P577
2009-03-27T00:00:00Z
P5875
P6179
1020696784